NO2694640T3
(sr)
*
|
2011-04-15 |
2018-03-17 |
|
|
JP6049712B2
(ja)
|
2011-07-08 |
2016-12-21 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill |
抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
|
BR112015022575B1
(pt)
*
|
2013-03-14 |
2022-03-22 |
Curadev Pharma Private Ltd |
Composto, pró-drogas de um composto, composição e método para preparar um composto
|
MA38493B1
(fr)
|
2013-03-14 |
2017-10-31 |
Newlink Genetics Corp |
Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
CN103382187B
(zh)
*
|
2013-08-06 |
2015-06-03 |
信实生物医药(上海)有限公司 |
一种3-氯-7(5)-溴苯并异恶唑的合成方法
|
PT3466949T
(pt)
|
2013-12-24 |
2021-02-25 |
Bristol Myers Squibb Co |
Composto tricíclico como agentes anticancro
|
WO2015187835A2
(en)
|
2014-06-06 |
2015-12-10 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
KR20170044144A
(ko)
*
|
2014-09-05 |
2017-04-24 |
메르크 파텐트 게엠베하 |
암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물
|
GB201417369D0
(en)
*
|
2014-10-01 |
2014-11-12 |
Redx Pharma Ltd |
Compounds
|
GB201418300D0
(en)
*
|
2014-10-15 |
2014-11-26 |
Redx Pharma Ltd |
Compounds
|
US10100129B2
(en)
|
2014-11-21 |
2018-10-16 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
WO2016100851A1
(en)
|
2014-12-18 |
2016-06-23 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
UY36471A
(es)
|
2014-12-23 |
2016-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim)
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
CN105884828A
(zh)
*
|
2015-02-16 |
2016-08-24 |
上海迪诺医药科技有限公司 |
多环化合物、其药物组合物及应用
|
MY186133A
(en)
|
2015-03-02 |
2021-06-24 |
Rigel Pharmaceuticals Inc |
Tgf-? inhibitors
|
JP2018519245A
(ja)
|
2015-04-03 |
2018-07-19 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の治療のためのインドールアミン−2,3−ジオキシゲナーゼの阻害剤およびそれらの使用方法
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
WO2016161960A1
(en)
|
2015-04-10 |
2016-10-13 |
Beigene, Ltd. |
NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
|
US10358451B2
(en)
|
2015-04-12 |
2019-07-23 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as IDO and TDO inhibitors
|
US20180085472A1
(en)
|
2015-04-13 |
2018-03-29 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
CN106715440B
(zh)
*
|
2015-04-21 |
2019-02-22 |
江苏恒瑞医药股份有限公司 |
咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
WO2016183115A1
(en)
|
2015-05-12 |
2016-11-17 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
MY188049A
(en)
|
2015-05-29 |
2021-11-12 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
GB2548542A
(en)
*
|
2015-06-16 |
2017-09-27 |
Redx Pharma Plc |
Compounds
|
CN106256830B
(zh)
*
|
2015-06-18 |
2019-03-08 |
成都海创药业有限公司 |
一种氘代的ido抑制剂及其制备方法和用途
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
CN105037371A
(zh)
*
|
2015-06-30 |
2015-11-11 |
西华大学 |
一种氘代的吲哚胺-2,3-双加氧酶抑制剂
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
EP3744340A3
(en)
|
2015-07-16 |
2021-03-03 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
KR20180086300A
(ko)
|
2015-07-24 |
2018-07-30 |
뉴링크 제네틱스 코퍼레이션 |
1-메틸-d-트립토판의 염 및 프로드러그
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
|
WO2017035118A1
(en)
|
2015-08-25 |
2017-03-02 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
CN106478634B
(zh)
*
|
2015-09-01 |
2020-05-22 |
尚华医药科技(江西)有限公司 |
稠合咪唑化合物、其制备方法、药物组合物和用途
|
US10308647B2
(en)
|
2015-10-29 |
2019-06-04 |
Scifluor Life Sciences, Inc. |
Fused imidazole derivatives as IDO/TDO inhibitors
|
PE20181300A1
(es)
|
2015-11-02 |
2018-08-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
|
CN108026565A
(zh)
*
|
2015-11-09 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
用于鉴定ido1和/或tdo调节剂的筛选测定法
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
CN108368174B
(zh)
|
2015-11-23 |
2023-04-14 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
WO2017106291A1
(en)
|
2015-12-15 |
2017-06-22 |
Bristol-Myers Squibb Company |
Cxcr4 receptor antagonists
|
US10800780B2
(en)
*
|
2015-12-24 |
2020-10-13 |
Genentech, Inc. |
TDO2 Inhibitors
|
CN107056785B
(zh)
*
|
2016-01-02 |
2021-06-22 |
杭州英创医药科技有限公司 |
作为ido和tdo抑制剂的杂环化合物
|
EP3400226A1
(en)
|
2016-02-02 |
2018-11-14 |
Emcure Pharmaceuticals Limited |
Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
|
US11752131B2
(en)
|
2016-02-19 |
2023-09-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
US10487088B2
(en)
|
2016-02-19 |
2019-11-26 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Tricyclic compound serving as immunomodulator
|
TW201736373A
(zh)
*
|
2016-02-19 |
2017-10-16 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
作為免疫調節劑的三並環化合物
|
WO2017149469A1
(en)
|
2016-03-03 |
2017-09-08 |
Emcure Pharmaceuticals Limited |
Heterocyclic compounds useful as ido and/or tdo modulators
|
JP2019514844A
(ja)
|
2016-03-04 |
2019-06-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗cd73抗体を用いた併用療法
|
CN105732643A
(zh)
*
|
2016-04-18 |
2016-07-06 |
苏州大学 |
一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
|
MX2018012757A
(es)
|
2016-04-18 |
2019-06-24 |
Celldex Therapeutics Inc |
Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
|
CN107312005B
(zh)
*
|
2016-04-27 |
2021-12-17 |
上海翰森生物医药科技有限公司 |
具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
|
EP3452450A1
(en)
|
2016-05-04 |
2019-03-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2019516682A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
US10323004B2
(en)
|
2016-05-04 |
2019-06-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN109414420A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
KR20190004742A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
EP3454862A4
(en)
|
2016-05-10 |
2020-02-12 |
C4 Therapeutics, Inc. |
SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
CN105902542A
(zh)
*
|
2016-05-16 |
2016-08-31 |
张阳 |
一种偶联物在制备治疗心血管疾病药物中的应用
|
CN107383012B
(zh)
*
|
2016-05-16 |
2021-09-28 |
鲁南制药集团股份有限公司 |
含二环的咪唑醇衍生物
|
CN107556316B
(zh)
*
|
2016-06-30 |
2021-11-12 |
鲁南制药集团股份有限公司 |
含桥环的咪唑衍生物
|
WO2017198159A1
(zh)
*
|
2016-05-16 |
2017-11-23 |
鲁南制药集团股份有限公司 |
含桥环的咪唑衍生物
|
CN106957318B
(zh)
*
|
2016-05-19 |
2019-12-10 |
中国科学院上海有机化学研究所 |
稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
|
WO2017201528A1
(en)
|
2016-05-20 |
2017-11-23 |
The University Of Chicago |
Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
|
AR108586A1
(es)
|
2016-06-10 |
2018-09-05 |
Lilly Co Eli |
Compuestos de 2,3-dihidro-1h-indol
|
CN107488179B
(zh)
*
|
2016-06-11 |
2024-06-07 |
鲁南制药集团股份有限公司 |
含桥环的咪唑醇衍生物
|
CN107556315B
(zh)
*
|
2016-06-30 |
2021-08-31 |
鲁南制药集团股份有限公司 |
含四元环的咪唑衍生物
|
MX2019000443A
(es)
|
2016-07-14 |
2019-06-20 |
Squibb Bristol Myers Co |
Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos.
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
CN107663159A
(zh)
*
|
2016-07-29 |
2018-02-06 |
上海迪诺医药科技有限公司 |
多环化合物、其药物组合物及应用
|
WO2018028491A1
(zh)
*
|
2016-08-09 |
2018-02-15 |
苏州国匡医药科技有限公司 |
吲哚胺2,3-双加氧酶抑制剂及其在药学中的用途
|
EP3503916A1
(en)
|
2016-08-26 |
2019-07-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN107383024B
(zh)
*
|
2016-09-12 |
2018-06-08 |
广州必贝特医药技术有限公司 |
含咪唑稠合三环类化合物及其应用
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ido及tdo調節之化合物及方法以及其適應症
|
US10882856B2
(en)
|
2016-09-24 |
2021-01-05 |
Beigene, Ltd. |
5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
TW201815417A
(zh)
*
|
2016-10-21 |
2018-05-01 |
蘇州盛迪亞生物醫藥有限公司 |
Pd-1抗體與ido抑制劑聯合在製備抗腫瘤的藥物中的用途
|
WO2018072742A1
(zh)
*
|
2016-10-21 |
2018-04-26 |
江苏恒瑞医药股份有限公司 |
一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
|
JP7096817B2
(ja)
|
2016-11-04 |
2022-07-06 |
オークランド ユニサービシーズ リミティド |
三環式複素環式誘導体及びその使用
|
CN106474468B
(zh)
*
|
2016-11-23 |
2020-03-27 |
中国医学科学院医学生物学研究所 |
一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
|
WO2018106579A1
(en)
*
|
2016-12-06 |
2018-06-14 |
Albert Einstein College Of Medicine, Inc. |
Drug targeting of human indoleamine 2,3-dioxygenase
|
WO2018113624A1
(zh)
*
|
2016-12-20 |
2018-06-28 |
深圳微芯生物科技有限责任公司 |
具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
|
US10287303B2
(en)
|
2016-12-22 |
2019-05-14 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
CN108239091B
(zh)
*
|
2016-12-26 |
2021-08-13 |
中国医学科学院药物研究所 |
1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
CN110191709A
(zh)
|
2017-01-17 |
2019-08-30 |
德州大学系统董事会 |
可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物
|
WO2018175954A1
(en)
|
2017-03-23 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
|
US20200031944A1
(en)
|
2017-03-31 |
2020-01-30 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
JP7232244B2
(ja)
|
2017-04-21 |
2023-03-08 |
イケナ オンコロジー, インコーポレイテッド |
インドールahr阻害剤およびその使用
|
AU2018258661A1
(en)
|
2017-04-28 |
2019-10-17 |
Five Prime Therapeutics, Inc. |
Methods of treatment with CD80 extracellular domain polypeptides
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN107176956B
(zh)
*
|
2017-05-31 |
2019-11-12 |
成都海博锐药业有限公司 |
一种ido抑制剂化合物、药用组合物、用途
|
US11603373B2
(en)
|
2017-06-28 |
2023-03-14 |
Genentech, Inc. |
TDO2 and IDO1 inhibitors
|
EP3645537A1
(en)
|
2017-06-28 |
2020-05-06 |
Genentech, Inc. |
Tdo2 and ido1 inhibitors
|
KR102630575B1
(ko)
|
2017-06-30 |
2024-01-29 |
브리스톨-마이어스 스큅 컴퍼니 |
Ido 억제제의 무정형 및 결정질 형태
|
JP7186764B2
(ja)
|
2017-07-28 |
2022-12-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
CN111194232B
(zh)
|
2017-08-02 |
2023-01-31 |
芝加哥大学 |
纳米级金属有机层和金属有机纳米片
|
TW201910336A
(zh)
*
|
2017-08-08 |
2019-03-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種咪唑并異吲哚類衍生物的製備方法
|
CN109384791B
(zh)
*
|
2017-08-09 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
|
WO2019034725A1
(en)
|
2017-08-17 |
2019-02-21 |
Idorsia Pharmaceuticals Ltd |
INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHAN DIOXYGENASE
|
MX2020001793A
(es)
|
2017-08-17 |
2020-07-22 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
|
US11236107B2
(en)
|
2017-08-18 |
2022-02-01 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
JP7316263B2
(ja)
|
2017-08-31 |
2023-07-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
CN107501272B
(zh)
*
|
2017-09-05 |
2020-03-31 |
中国药科大学 |
咪唑并异吲哚类ido1抑制剂、其制备方法及应用
|
WO2019055786A1
(en)
|
2017-09-14 |
2019-03-21 |
Lankenau Institute For Medical Research |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
EP3684365A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND USES OF SUCH
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
JP7212683B2
(ja)
|
2017-10-10 |
2023-01-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
KR20200065065A
(ko)
|
2017-10-16 |
2020-06-08 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
CN111386114A
(zh)
|
2017-11-25 |
2020-07-07 |
百济神州有限公司 |
作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
|
EP3731869A4
(en)
|
2017-12-26 |
2021-09-22 |
Kymera Therapeutics, Inc. |
KINASES IRAQ DEGRADATION AGENTS AND THEIR USES
|
US11306149B2
(en)
|
2017-12-27 |
2022-04-19 |
Bristol-Myers Squibb Company |
Anti-CD40 antibodies and uses thereof
|
WO2019136112A1
(en)
|
2018-01-05 |
2019-07-11 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3737700A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019138107A1
(en)
|
2018-01-15 |
2019-07-18 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
CN111247119B
(zh)
*
|
2018-01-19 |
2023-02-03 |
四川科伦博泰生物医药股份有限公司 |
脒类和胍类衍生物、其制备方法及其在医药上的应用
|
AU2019212969A1
(en)
|
2018-01-29 |
2020-08-13 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
US10988477B2
(en)
|
2018-01-29 |
2021-04-27 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
EP3762397B1
(en)
|
2018-03-08 |
2024-05-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
JP2021518367A
(ja)
|
2018-03-20 |
2021-08-02 |
プレキシコン インコーポレーテッドPlexxikon Inc. |
Idoおよびtdo調節のための化合物および方法、ならびにそれらのための兆候
|
US20210017283A1
(en)
|
2018-03-21 |
2021-01-21 |
Five Prime Therapeutics, Inc. |
Antibodies Binding to Vista at Acidic pH
|
WO2019183551A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
KR20200142542A
(ko)
|
2018-04-12 |
2020-12-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
|
WO2019204257A1
(en)
|
2018-04-16 |
2019-10-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
US20230339891A1
(en)
|
2018-05-03 |
2023-10-26 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
JP7373512B2
(ja)
|
2018-06-27 |
2023-11-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用なナフチリジノン化合物
|
SG11202012972YA
(en)
|
2018-06-27 |
2021-01-28 |
Bristol Myers Squibb Co |
Substituted naphthyridinone compounds useful as t cell activators
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
TWI819024B
(zh)
|
2018-07-09 |
2023-10-21 |
美商戊瑞治療有限公司 |
結合至ilt4的抗體
|
TW202028235A
(zh)
|
2018-07-11 |
2020-08-01 |
美商戊瑞治療有限公司 |
於酸性ph結合至含免疫球蛋白v域之t細胞活化抑制子(vista)之抗體
|
WO2020018670A1
(en)
|
2018-07-17 |
2020-01-23 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
US20210299126A1
(en)
|
2018-07-23 |
2021-09-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2022500499A
(ja)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス, インコーポレイテッド |
Eif4e阻害剤およびその使用
|
CN110950842B
(zh)
*
|
2018-09-27 |
2023-06-20 |
深圳微芯生物科技股份有限公司 |
具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
KR20210092769A
(ko)
|
2018-11-16 |
2021-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항-nkg2a 항체 및 그의 용도
|
MX2021006154A
(es)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN DEGRADATION
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
WO2020206424A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
EP3976192A1
(en)
|
2019-05-31 |
2022-04-06 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2021005222A1
(en)
|
2019-07-11 |
2021-01-14 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
MX2022005839A
(es)
|
2019-11-19 |
2022-06-09 |
Bristol Myers Squibb Co |
Compuestos utiles como inhibidores de la proteina helios.
|
CA3159071A1
(en)
|
2019-11-26 |
2021-06-03 |
Tamar I. ROSENBAUM |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
WO2021108528A1
(en)
|
2019-11-26 |
2021-06-03 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
CN111333653A
(zh)
*
|
2019-12-16 |
2020-06-26 |
山东大学 |
一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
|
CN115052627A
(zh)
|
2019-12-17 |
2022-09-13 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
CA3162979A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted piperazine derivatives useful as t cell activators
|
CN114846007A
(zh)
|
2019-12-23 |
2022-08-02 |
百时美施贵宝公司 |
可用作t细胞激活剂的经取代的喹唑啉基化合物
|
EP4081524A1
(en)
|
2019-12-23 |
2022-11-02 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
AU2020412780A1
(en)
|
2019-12-23 |
2022-07-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
US20230061608A1
(en)
|
2019-12-23 |
2023-03-02 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
US20230045791A1
(en)
|
2020-01-06 |
2023-02-16 |
Hifibio (Hk) Limited |
Anti-tnfr2 antibody and uses thereof
|
EP4087873A1
(en)
|
2020-01-07 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-galectin-9 antibody and uses thereof
|
CN115279771A
(zh)
|
2020-01-15 |
2022-11-01 |
缆图药品公司 |
Map4k1抑制剂
|
CA3170411A1
(en)
|
2020-03-03 |
2021-09-10 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
IL296451A
(en)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
mdm2 joints and their uses
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CN111803635B
(zh)
*
|
2020-06-17 |
2023-03-14 |
中国医学科学院基础医学研究所 |
小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
MX2023001217A
(es)
|
2020-07-30 |
2023-03-03 |
Kymera Therapeutics Inc |
Metodos de tratamiento de linfomas mutantes.
|
WO2022033419A2
(en)
|
2020-08-10 |
2022-02-17 |
Shanghai Xbh Biotechnology Co., Ltd. |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
MX2023001588A
(es)
|
2020-08-17 |
2023-05-03 |
Bicycletx Ltd |
Conjugados biciclo específicos para nectina-4 y usos de estos.
|
US20230416382A1
(en)
|
2020-10-14 |
2023-12-28 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
TEAD inhibitors and their uses
|
WO2022133083A1
(en)
|
2020-12-16 |
2022-06-23 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
EP4274597A1
(en)
|
2021-01-11 |
2023-11-15 |
BicycleTX Limited |
Methods for treating cancer
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Gpr84アンタゴニストおよびその使用
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
MX2023009379A
(es)
|
2021-02-12 |
2023-10-10 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
WO2022184930A2
(en)
|
2021-03-05 |
2022-09-09 |
Universität Basel |
Compositions for the treatment of ebv associated diseases or conditions
|
EP4052705A1
(en)
|
2021-03-05 |
2022-09-07 |
Universität Basel Vizerektorat Forschung |
Compositions for the treatment of ebv associated diseases or conditions
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Map4k1阻害剤
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
AR125298A1
(es)
|
2021-04-06 |
2023-07-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
AR126442A1
(es)
|
2021-07-14 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
AR126453A1
(es)
|
2021-07-15 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|